1 |
Implication de la voie Prostaglandine D synthase/PGD2/SOX9 dans l'ovaire normal et pathologique et régulation par la signalisation estrogénique / Implication of the Prostaglandin D synthase/PGD2/SOX9 pathway in the normal and pathological ovary and regulation by estrogenic signallingFarhat, Andalib 15 June 2010 (has links)
L'ovaire représente à la fois un organe cible et le principal organe producteur d'estrogènes et de progestérone qui maintiennent le développement des caractères sexuels féminins et une fonction de reproduction normale. Cette production hormonale est contrôlée par les gonadotropines FSH et LH produites dans l'hypophyse, responsables dans l'ovaire de la croissance folliculaire et de l'ovulation, respectivement. Mon travail de thèse a identifié la signalisation prostaglandine D2 (PGD2), comme un nouvel élément-clé dans la signalisation des gonadotropines, contribuant à l'activation de l'expression des récepteurs FshR et LhR et des enzymes de la stéroïdogenèse SCC et StAR. La PGD2, produite dans plusieurs tissus par deux enzymes de synthèse, les prostaglandines synthases H et L-PGDS, est impliquée dans de nombreuses fonctions physiologiques et pathologiques. Comme dans l'ovaire pathologique, nous avons montré que la PGD2 avait aussi un rôle anti-prolifératif dans la cellule de granulosa de l'ovaire normal. Le cancer de l'ovaire représente la 4ème cause de mortalité par cancer chez la femme. Les mécanismes moléculaires impliqués dans le développement de ces tumeurs sont encore peu connus, bien que l'implication des estrogènes et de la Prostaglandine E2 (PGE2) dans la progression des tumeurs ovariennes épithéliales soit bien établie. D'autre part, les ovaires des souris invalidées pour les gènes codant les récepteurs aux estrogènes ou l'aromatase, possèdent des structures tubulaires contenant des cellules de Leydig et des cellules de Sertoli re-différenciées exprimant le facteur de détermination sexuelle mâle SOX9, alors qu'il n'est pas exprimé dans l'ovaire sain. Mon travail a montré que les estrogènes inhibent la transcription des gènes Sox9 et L-Pgds dans les lignées ovariennes tumorales BG1 et COV434 et que cette régulation est la résultante d'une inhibition, via le récepteur ERa et d'une activation via le récepteur ERß. Ces résultats sont en accord avec les études sur les effets prolifératifs d'ERa et le rôle anti-prolifératif d'ERß et suggèrent donc un rôle anti-prolifératif de la PGD2 dans l'ovaire tumoral et une régulation négative directe ou indirecte de l'expression de Sox9 et des Pgds par les estrogènes. / The prostaglandin D2 (PGD2) pathway is involved in numerous biological processes and while it has been identified as a partner of the embryonic sex determining male cascade, the roles it plays in ovarian function remain largely unknown. PGD2 is secreted by two prostaglandin D synthases (Pgds); the male-specific lipocalin (L)-Pgds and the hematopoietic (H)-Pgds. Here, we report the localization of H-Pgds mRNA in the granulosa cells from the primary to pre-ovulatory follicles. We used adult female mice treated with HQL-79, a specific inhibitor of H-Pgds enzymatic activity, to provide evidence of an interaction between H-Pgds-produced PGD2 signaling and FSH signaling. This leads to the activation of steroidogenic Scc and StAR gene expression through increased FshR and LhR receptor expression leading to progesterone secretion. We also identify a role whereby H-Pgds-produced PGD2 is involved in the regulation of follicular growth through inhibition of granulosa cell proliferation in the growing follicles. Indeed, we report an altered H-Pgds expression in human ovarian tumors alongside a partial or complete absence of H-Pgds protein in granulosa cell tumors, suggesting a potential association between decreased levels of H-Pgds expression and a tumoral phenotype. Together, these results show PGD2 signaling to be essential for FSH action within granulosa cells, thus identifying an important and unappreciated role for PGD2 signaling in controlling the balance of proliferation, differentiation and steroidogenic activity of these cells.
|
2 |
Analysis of how the production and activity of PGD2 affects glioma cell lines. / Análise de como a produção e atividade de PGD2 afetam linhagens de glioma.Ferreira, Matthew Thomas 30 January 2015 (has links)
The World Health Organization classifies glioblastoma (GBM) as a type IV astrocytoma, making it one of the most fatal tumors that exists. Despite the advances in chemotherapy, surgery, and radiation treatments that improve a patients length of survival, the overall trajectory of the disease remains unchanged. It has been shown that GBM cells produce significant levels of prostaglandins, including prostaglandin D2 (PGD2). PGD2 possesses pro- and anti-tumorigenic properties. Hence, a more complete understanding of PGD2 activity in GBM could yield more effective treatments against GBM. Through techniques like RT-PCR, immunohistochemistry, and HPLC tandem mass spectrometry, we were able to confirm the presence of the PGD2 synthesis in GBM cell lines. We treated GBM cell lines with various concentrations of exogenous PGD2 over 72 hours and observed its effects on cell count, apoptosis, mitosis and viability. Our results suggest that PGD2 possesses contradictory functions in GBM depending on concentration (mM PGD2 vs. nM PGD2) and receptor activation. / A Organização Mundial de Saúde classifica glioblastoma (GBM) como um astrocitoma tipo IV, fazendo uns dos tumores mais fatais que existe. A pesar dos avanços em quimioterapia, cirurgia e radioterapia que melhoram a longevidade de sobrevivência, a trajetória geral da doença permanece imutável. Tem sido demonstrado que células de GBM produzem níveis significativos de prostaglandinas, incluindo prostaglandina D2 (PGD2). PGD2 possui propriedades pro- e anti-tumorigenicos. Então, um entendimento mais completo da atividade de PGD2 em GBM pode gerar tratamentos mais efetivos. Através de técnicas como RT-PCR, imunohistoquimicas e HPLC espectrometria de massa em tandem, conseguimos confirmar a presença da síntese de PGD2 em linhagens de GBM. Tratamos linhagens de GBM com concentrações variáveis de PGD2 exógeno durante 72 horas e observamos seus efeitos na contagem de células, apoptose, mitose e viabilidade. Nossos resultados sugerem que PGD2 possui funções opostas em GBM dependendo em concentração (mM PGD2 vs. nM PGD2) e ativação de receptores.
|
3 |
Analysis of how the production and activity of PGD2 affects glioma cell lines. / Análise de como a produção e atividade de PGD2 afetam linhagens de glioma.Matthew Thomas Ferreira 30 January 2015 (has links)
The World Health Organization classifies glioblastoma (GBM) as a type IV astrocytoma, making it one of the most fatal tumors that exists. Despite the advances in chemotherapy, surgery, and radiation treatments that improve a patients length of survival, the overall trajectory of the disease remains unchanged. It has been shown that GBM cells produce significant levels of prostaglandins, including prostaglandin D2 (PGD2). PGD2 possesses pro- and anti-tumorigenic properties. Hence, a more complete understanding of PGD2 activity in GBM could yield more effective treatments against GBM. Through techniques like RT-PCR, immunohistochemistry, and HPLC tandem mass spectrometry, we were able to confirm the presence of the PGD2 synthesis in GBM cell lines. We treated GBM cell lines with various concentrations of exogenous PGD2 over 72 hours and observed its effects on cell count, apoptosis, mitosis and viability. Our results suggest that PGD2 possesses contradictory functions in GBM depending on concentration (mM PGD2 vs. nM PGD2) and receptor activation. / A Organização Mundial de Saúde classifica glioblastoma (GBM) como um astrocitoma tipo IV, fazendo uns dos tumores mais fatais que existe. A pesar dos avanços em quimioterapia, cirurgia e radioterapia que melhoram a longevidade de sobrevivência, a trajetória geral da doença permanece imutável. Tem sido demonstrado que células de GBM produzem níveis significativos de prostaglandinas, incluindo prostaglandina D2 (PGD2). PGD2 possui propriedades pro- e anti-tumorigenicos. Então, um entendimento mais completo da atividade de PGD2 em GBM pode gerar tratamentos mais efetivos. Através de técnicas como RT-PCR, imunohistoquimicas e HPLC espectrometria de massa em tandem, conseguimos confirmar a presença da síntese de PGD2 em linhagens de GBM. Tratamos linhagens de GBM com concentrações variáveis de PGD2 exógeno durante 72 horas e observamos seus efeitos na contagem de células, apoptose, mitose e viabilidade. Nossos resultados sugerem que PGD2 possui funções opostas em GBM dependendo em concentração (mM PGD2 vs. nM PGD2) e ativação de receptores.
|
4 |
Améliorer les effets anti-tumoraux des lymphocytes T folliculaires helper (Tfh) en ciblant la communication intercellulaire entre Tfh et Th2. / Improvement of the anti-tumoral effects of T follicular helper cells (Tfh) by the targeting of the intercellular cross-talk between Tfh and Th2 cells.Mary, Romain 09 October 2019 (has links)
Il est maintenant acquis que le système immunitaire occupe une place importante dans l’évolution les cancers (Hanahan et al., 2011). La compréhension actuelle de la réponse immunitaire adaptative en fait une cible de choix dans ce contexte. Il est apparu que les lymphocytes T CD4+, acteurs majeurs de la composante adaptative du système immunitaire, présentent des actions distinctes sur le contrôle de la croissance tumorale. Ainsi, les lymphocytes Th2 et Tfh, tous deux activateurs des lymphocytes B dans des conditions de lutte contre des infections pathogéniques, présentent des rôles ambivalents dans un contexte de cancer. En effet, de nombreuses études montrent que la présence de Th2 est corrélée à une progression de la maladie (notamment via l’action de l’IL-4 qu’ils sécrètent) (Koller et al., 2010 ; Roca et al., 2012) alors que les Tfh, seraient plutôt associés à un bon pronostic pour les patients (Gu-Trantien et al., 2013, 2017).Nos investigations actuelles nous ont permis de mettre en avant une caractéristique nouvelle de la biologie des lymphocytes Tfh. En effet, les Tfh expriment l’Hemathopoietic Prostaglandin D2 synthase (HPGDS). Cette enzyme de la voie de biosynthèse des eicosanoïdes est responsable de la production de Prostaglandine D2 (PGD2). Plusieurs travaux montrent que les cellules Th2 expriment le récepteur CRTH2, spécifique de la PGD2. Cette molécule agit sur ces cellules comme chemoattractant et permet également une augmentation de leur production cytokinique. Ainsi, nous posons l’hypothèse d’une communication potentielle entre lymphocytes Tfh et Th2 via la PGD2. Le projet présenté ici est alors axé sur la compréhension des mécanismes moléculaires et cellulaires sous-jacent à cette communication au sein des deux sous-types ainsi que sur son impact dans un contexte de cancer. Ce projet ayant également pour but de mettre en avant la PGD2 comme nouvelle cible thérapeutique dans le cancer. / It is now accepted that the immune system plays a critical role in cancers evolution (Hanahan et al., 2011). In this context, current understanding of the adaptive immune response made it a prime target. T CD4 cells, the main players of the adaptive immune system component, are known to possess distinct roles in the control of tumour growth. Thereby, Th2 and Tfh cells, both known to activate B cells in pathogenic infections, present antagonistic roles in cancer. Indeed, numerous studies demonstrate that Th2 cells are correlated with disease progression (especially via IL-4 secretion) (Koller et al., 2010 ; Roca et al., 2012), whereas Tfh cells are associated with a good prognosis for the patients (Gu-Trantien et al., 2013, 2017) despite the actual limited amount of available data.Our current researches highlighted a new property of the biology of Tfh cells. We found that Tfh cells are able to express the Hemathopoietic Prostaglandin D2 synthase (HPGDS), an eicosanoid pathway enzyme involved in Prostaglandin D2 (PGD2) production. Moreover, different studies revealed that Th2 cells expressed CRTH2, the specific PGD2 receptor. PGD2 is known as a chemoattractant molecule for Th2 cells and lead to the increase of their cytokine secretion. We hypothesized that Tfh communicate with Th2 cells via PGD2 signalling. The present project is focused on the understanding of the underlying molecular and cellular mechanisms involved in this cross-talk and their impact in cancer. The last aim of this work is to favor the development of PGD2 as a new cancer therapeutic target.
|
5 |
Sulfeto de hidrogênio durante o choque endotoxêmico: modulação da produção de PGD2 na AVPO e de citocinas periféricas durante as fases de hipotermia e febre / Hydrogen sulfide during endotoxic shock: Modulation of PGD2 production in AVPO and peripheral cytokines during hypothermia and feverFernández, Rodrigo Alberto Restrepo 25 August 2017 (has links)
As respostas termorregulatórias ao lipopolissacarídeo (LPS) são influenciadas por moduladores que aumentam (febrigênicos) ou diminuem (criogênicos) a temperatura corporal (Tb). Entre eles, o neurotransmissor gasoso sulfeto de hidrogênio (H2S) modula a inflamação sistêmica induzida por endotoxina em ratos, agindo como uma molécula anti-inflamatória e criogênica, embora os mecanismos subjacentes ainda sejam pouco compreendidos. Considerando que a endotoxina é um ligando para o Toll-like receptor 4 (TLR4) e que evidências recentes revelam um cross-talk entre a via de sinalização TLR e fosfo-Akt (p-Akt), o objetivo do presente estudo foi investigar se o H2S atua como um mediador antiinflamatório e antipirético durante as fases termorregulatórias que ocorrem no choque endotoxêmico (hipotermia e febre) induzido por lipopolissacarídeo bacteriano (LPS, 2,5 mg / kg intraperitoneal (ip)) através da modulação sobre a produção de prostaglandina D2 (PGD2) e a ativação de Akt na área pré-óptica ântero-ventral do hipotálamo (AVPO). A Tb profunda de ratos mantidos a uma temperatura ambiente de 25 °C foi registrada antes e depois da inibição farmacológica da enzima cistationina ?-sintase (CBS - responsável pela produção endógena de H2S no cérebro) usando aminooxiacetato (AOA, 100 pmol, intracerebroventricular (icv)), combinado ou não com administração de LPS. Para esclarecer os mecanismos responsáveis por esses ajustes da resposta imune, foram determinados na AVPO os níveis de H2S, a produção de PGD2 e o perfil de expressão das proteínas CBS, p-Akt e p-CREB. Além disso, foi analisada a concentração de citocinas plasmáticas (IL-1?, IL-6, IL-10, TNF?, IFN-? , E IL-4). A injeção ip de LPS causou hipotermia típica seguida de febre. Os níveis de AVPO H2S aumentaram significativamente durante a hipotermia quando comparado com ratos eutérmicos e febris. A microinjeção icv de AOA não causou nenhuma alteração na Tb nem na produção basal de PGD2 durante a eutermia. Em ratos tratados com LPS, o AOA causou uma atenuação na queda da Tb durante a fase de hipotermia e uma febre exacerbada, simultaneamente com o aumento na produção de PGD2 e abolição do aumento induzido pela endotoxina na atividade de Akt. Durante a fase de febre, a expressão relativa de CBS esteve significativamente diminuída enquanto a expressão relativa de p-Akt esteve aumentada, quando comparado com ratos eutérmicos e hipotérmicos. As citocinas plasmáticas aumentaram durante a inflamação sistêmica, mas apenas a IL-4 mostrou um padrão semelhante em relação à Akt. Estes dados são consistentes com a noção de que o neurotransmissor gasoso H2S modula as fases de hipotermia e febre durante o choque endotoxêmico, atuando como uma molécula criogênica. Este papel anti-inflamatório durante a inflamação sistémica envolve uma regulação positiva da PGD2, de Akt e da IL-4 plasmática. / Thermoregulatory responses to lipopolysaccharide (LPS) are affected by modulators that increase (pro-pyretic) or decrease (cryogenic) body temperature (Tb). Among them, the gaseous messenger hydrogen sulfide (H2S) modulates endotoxin-induced systemic inflammation being an anti-inflammatory and cryogenic molecule, although the underlying mechanisms are still poorly understood. Since endotoxin is a Toll-like receptor 4 (TLR4) ligand and recent evidence indicates that there is a possible a cross-talk between the TLR and phospho-Akt (p-Akt) signaling pathway, the current study aimed to investigate whether H2S acts as an anti-inflammatory and anti-pyretic mediator during thermoregulatory phases of endotoxic shock (hypothermia and fever) induced by bacterial lipopolysaccharide (LPS, 2.5 mg/kg intraperitoneal (ip)) through the modulation of prostaglandin D2 (PGD2) production and activation of Akt in the anteroventral preoptic region of the hypothalamus (AVPO). Deep Tb in rats kept at an ambient temperature of 25 °C, was recorded before and after pharmacological inhibition of the enzyme cystathionine ?-synthase (CBS - responsible for H 2S endogenous production in the brain) using aminooxyacetate (AOA; 100 pmol/1 ?l intracerebroventricular (icv)) combined or not with endotoxin administration. To clarify the mechanisms responsible for these adjustments on immune response were verified in the AVPO H 2S levels, PGD2 production and expression profiles of CBS, p-Akt and p-CREB. In addition, plasma cytokines concentration (IL-1?, IL-6, IL-10, TNF?, IFN-?, and IL-4) was analyzed. Intraperitoneal injection of LPS caused typical hypothermia followed by fever. Intracerebroventricular microinjection of AOA neither affected Tb nor basal PGD2 production during euthermia. Levels of AVPO H2S were significantly increased during hypothermia when compared to both euthermic and febrile rats. In LPS-treated rats, AOA increased Tb values during hypothermia and fever, along with enhanced PGD2 production and abolition of endotoxin-induced increase in Akt activity. During fever, CBS relative expression was significantly decreased whereas p-Akt was significantly increased when compared to both euthermic and hypothermic rats. Plasma cytokines were increased during systemic inflammation, but only IL-4 showed a similar pattern in relation to Akt. These data are consistent with the notion that the gaseous messenger H2S modulates hypothermia and fever during endotoxic shock, acting as a cryogenic molecule. This anti-inflammatory role during systemic inflammation involves a H2S-induced up-modulation of PGD2, Akt and plasma IL-4.
|
6 |
Sulfeto de hidrogênio durante o choque endotoxêmico: modulação da produção de PGD2 na AVPO e de citocinas periféricas durante as fases de hipotermia e febre / Hydrogen sulfide during endotoxic shock: Modulation of PGD2 production in AVPO and peripheral cytokines during hypothermia and feverRodrigo Alberto Restrepo Fernández 25 August 2017 (has links)
As respostas termorregulatórias ao lipopolissacarídeo (LPS) são influenciadas por moduladores que aumentam (febrigênicos) ou diminuem (criogênicos) a temperatura corporal (Tb). Entre eles, o neurotransmissor gasoso sulfeto de hidrogênio (H2S) modula a inflamação sistêmica induzida por endotoxina em ratos, agindo como uma molécula anti-inflamatória e criogênica, embora os mecanismos subjacentes ainda sejam pouco compreendidos. Considerando que a endotoxina é um ligando para o Toll-like receptor 4 (TLR4) e que evidências recentes revelam um cross-talk entre a via de sinalização TLR e fosfo-Akt (p-Akt), o objetivo do presente estudo foi investigar se o H2S atua como um mediador antiinflamatório e antipirético durante as fases termorregulatórias que ocorrem no choque endotoxêmico (hipotermia e febre) induzido por lipopolissacarídeo bacteriano (LPS, 2,5 mg / kg intraperitoneal (ip)) através da modulação sobre a produção de prostaglandina D2 (PGD2) e a ativação de Akt na área pré-óptica ântero-ventral do hipotálamo (AVPO). A Tb profunda de ratos mantidos a uma temperatura ambiente de 25 °C foi registrada antes e depois da inibição farmacológica da enzima cistationina ?-sintase (CBS - responsável pela produção endógena de H2S no cérebro) usando aminooxiacetato (AOA, 100 pmol, intracerebroventricular (icv)), combinado ou não com administração de LPS. Para esclarecer os mecanismos responsáveis por esses ajustes da resposta imune, foram determinados na AVPO os níveis de H2S, a produção de PGD2 e o perfil de expressão das proteínas CBS, p-Akt e p-CREB. Além disso, foi analisada a concentração de citocinas plasmáticas (IL-1?, IL-6, IL-10, TNF?, IFN-? , E IL-4). A injeção ip de LPS causou hipotermia típica seguida de febre. Os níveis de AVPO H2S aumentaram significativamente durante a hipotermia quando comparado com ratos eutérmicos e febris. A microinjeção icv de AOA não causou nenhuma alteração na Tb nem na produção basal de PGD2 durante a eutermia. Em ratos tratados com LPS, o AOA causou uma atenuação na queda da Tb durante a fase de hipotermia e uma febre exacerbada, simultaneamente com o aumento na produção de PGD2 e abolição do aumento induzido pela endotoxina na atividade de Akt. Durante a fase de febre, a expressão relativa de CBS esteve significativamente diminuída enquanto a expressão relativa de p-Akt esteve aumentada, quando comparado com ratos eutérmicos e hipotérmicos. As citocinas plasmáticas aumentaram durante a inflamação sistêmica, mas apenas a IL-4 mostrou um padrão semelhante em relação à Akt. Estes dados são consistentes com a noção de que o neurotransmissor gasoso H2S modula as fases de hipotermia e febre durante o choque endotoxêmico, atuando como uma molécula criogênica. Este papel anti-inflamatório durante a inflamação sistémica envolve uma regulação positiva da PGD2, de Akt e da IL-4 plasmática. / Thermoregulatory responses to lipopolysaccharide (LPS) are affected by modulators that increase (pro-pyretic) or decrease (cryogenic) body temperature (Tb). Among them, the gaseous messenger hydrogen sulfide (H2S) modulates endotoxin-induced systemic inflammation being an anti-inflammatory and cryogenic molecule, although the underlying mechanisms are still poorly understood. Since endotoxin is a Toll-like receptor 4 (TLR4) ligand and recent evidence indicates that there is a possible a cross-talk between the TLR and phospho-Akt (p-Akt) signaling pathway, the current study aimed to investigate whether H2S acts as an anti-inflammatory and anti-pyretic mediator during thermoregulatory phases of endotoxic shock (hypothermia and fever) induced by bacterial lipopolysaccharide (LPS, 2.5 mg/kg intraperitoneal (ip)) through the modulation of prostaglandin D2 (PGD2) production and activation of Akt in the anteroventral preoptic region of the hypothalamus (AVPO). Deep Tb in rats kept at an ambient temperature of 25 °C, was recorded before and after pharmacological inhibition of the enzyme cystathionine ?-synthase (CBS - responsible for H 2S endogenous production in the brain) using aminooxyacetate (AOA; 100 pmol/1 ?l intracerebroventricular (icv)) combined or not with endotoxin administration. To clarify the mechanisms responsible for these adjustments on immune response were verified in the AVPO H 2S levels, PGD2 production and expression profiles of CBS, p-Akt and p-CREB. In addition, plasma cytokines concentration (IL-1?, IL-6, IL-10, TNF?, IFN-?, and IL-4) was analyzed. Intraperitoneal injection of LPS caused typical hypothermia followed by fever. Intracerebroventricular microinjection of AOA neither affected Tb nor basal PGD2 production during euthermia. Levels of AVPO H2S were significantly increased during hypothermia when compared to both euthermic and febrile rats. In LPS-treated rats, AOA increased Tb values during hypothermia and fever, along with enhanced PGD2 production and abolition of endotoxin-induced increase in Akt activity. During fever, CBS relative expression was significantly decreased whereas p-Akt was significantly increased when compared to both euthermic and hypothermic rats. Plasma cytokines were increased during systemic inflammation, but only IL-4 showed a similar pattern in relation to Akt. These data are consistent with the notion that the gaseous messenger H2S modulates hypothermia and fever during endotoxic shock, acting as a cryogenic molecule. This anti-inflammatory role during systemic inflammation involves a H2S-induced up-modulation of PGD2, Akt and plasma IL-4.
|
7 |
Rôle de la voie L-PGDS / PGD2 / DP1 dans l’OstéoArthroseOuhaddi, Yassine 04 1900 (has links)
L'arthrose (OA) est la maladie dégénérative la plus fréquente (ou) et la principale cause d'incapacité physique avec un coût socioéconomique important. Les manifestations cliniques de l'arthrose peuvent inclure des douleurs, des raideurs et des mouvements articulaires réduits. Pathologiquement, l'OA se caractérise par une dégénérescence progressive du cartilage articulaire, une augmentation de l'expression des médiateurs inflammatoires et cataboliques et le remodelage osseux sous-chondral.
Il a été démontré que la protéine prostaglandine D2 (PGD2) est synthétisée par différents types cellulaires et possède des propriétés pro et anti-inflammatoires, selon le récepteur activé. Plusieurs stimuli pro-inflammatoires ont été discernés et étudiés, mais par contre, les voies anti-inflammatoires restent toujours un univers inexploré. Le récepteur DP1 de la PGD2, ainsi que l’enzyme de synthèse L-PGDS, jouent des rôles importants dans l'inflammation et le métabolisme du cartilage. Cependant, leurs rôles dans la pathogenèse de l'arthrose (OA) restent inconnus.
Nous avons entrepris l’étude (de quoi) d’une part, pour explorer les rôles de la L- PGDS et de DP1 dans le développement d'OA, et d’autre part pour évaluer l'efficacité d'un agoniste sélectif de DP1 et d’un virus d'AAV2 / 5 codant pour L-PGDS dans le traitement de l'OA. En premier, nos travaux par histologie ont démontré que la dégradation du cartilage est plus prononcée chez les souris Knock-out L-PGDS et DP1, comparativement au souris sauvages Wild-Type (WT). Ensuite une augmentation de l’expression des médiateurs cataboliques (ADAMTS5 et MMP-13), chez les souris L-PGDS -/- et DP1 -/- par rapport au WT a été démontré. Après, la stimulation des explants de cartilage des souris L-PGDS -/- et de DP1 -/- avec l’IL-1a, ont montré une dégradation élevée en protéoglycanes. En outre ces souris ont développer aussi des modifications osseuses sous- chondral. Enfin, nos résultats suggèrent qu’à la suite d'injection intrapéritonéale de l’agoniste spécifique de DP1, le BW245C a atténué la gravité de la dégradation du cartilage induite par une déstabilisation du ménisque médiale (DMM) et des modifications osseuses chez les souris WT. Pareillement, l'injection intra-auriculaire d'AAV2 / 5 codant pour L- PGDS a atténué aussi la dégradation du cartilage induite par DMM et l'expression de ADAMTS-5 et MMP-13 chez des souris L-PGDS -/-.
En conclusion, l’ensemble de nos résultats suggèrentque le récepteur DP1 et l’enzyme L-PGDS au niveau du cartilage articulaire arthrosique joue un rôle très important. . Elle pourrait constituer une voie thérapeutique potentielle dans le traitement de l’OA et aussi dans le traitement d’autres pathologies musculo-squelettiques. / Osteoarthritis (OA) is the most common degenerative disease (or) and the leading cause of physical disability with significant socioeconomic costs. Clinical manifestations of osteoarthritis can include pain, stiffness, and reduced joint movement. Pathologically, OA is characterized by progressive degeneration of articular cartilage, increased expression of inflammatory and catabolic mediators, and subchondral bone remodeling.
It has been shown that prostaglandin D2 protein (PGD2) is synthesized by different cell types and has pro and anti-inflammatory properties, depending on the activated receptor. Several pro-inflammatory stimuli have been discerned and studied, but the anti- inflammatory pathways remain an unexplored universe. The DP1 receptor of PGD2, as well as the synthetic enzyme L-PGDS, play important roles in inflammation and cartilage metabolism. However, their roles in the pathogenesis of osteoarthritis (OA) remain unknown.
We undertook the study (of what) on the one hand, to explore the roles of L-PGDS and DP1 in the development of OA, and on the other hand to evaluate the efficacy of a selective agonist DP1 and an AAV2 / 5 virus encoding L-PGDS in the treatment of OA. First, our histology work demonstrated that cartilage degradation is more pronounced in L- PGDS Knock-out and DP1 mice compared to Wild-Type (WT) wild-type mice. Then an increase in the expression of catabolic mediators (ADAMTS5 and MMP-13), in L-PGDS - / - mice and DP1 - / - compared to WT was demonstrated. Subsequently, stimulation of cartilage explants with IL-α from L-PGDS - / - and DP1 - / - mice showed high degradation in proteoglycans. In addition, these mice also develop subchondral bone changes. Finally, our results suggest that following intraperitoneal injection of the DP1-specific agonist, BW245C attenuated the severity of cartilage degradation induced by medial meniscus destabilization (DMM) and bone changes in mice. WT. Similarly, the intra-atrial injection of AAV2 / 5 encoding L-PGDS also attenuated DMM-induced cartilage degradation and the expression of ADAMTS-5 and MMP-13 in L-PGDS - / - mice.
In conclusion, all our results suggest that the recepteur DP1 and the L-PGDS enzyme in osteorthritis cartilage plays a very important role. It may be a potential therapeutic avenue in the treatment of OA and also in the treatment of other musculoskeletal conditions.
|
8 |
Rôle de la voie PGD2/L-PGDS dans la physiopathologie de l’arthroseZayed, Nadia 06 1900 (has links)
No description available.
|
9 |
Rôle de la voie PGD2/L-PGDS dans la physiopathologie de l’arthroseZayed, Nadia 06 1900 (has links)
L’arthrose (OA) est la maladie articulaire la plus répandue dans le monde faisant l’objet de nombreux travaux de recherche en raison de son lourd impact socioéconomique. Plusieurs travaux dans ce domaine ont pour objectif de déterminer les mécanismes moléculaires impliqués dans sa physiopathologie. Plusieurs travaux ont appuyés l’implication de la prostaglandine (E2) PGE2 dans sa physiopathologie, contrairement à la prostaglandine (D2) (PGD2) dont le rôle reste à déterminer. C’est pourquoi, nous nous sommes penchés dans cette thèse à l’étude de cette dernière molécule.
Dans la première partie de nos travaux, nous avons montré que la PGD2 diminue au niveau du cartilage articulaire et au niveau niveau des explants de cartilage humains, la production des métalloprotéases-1(MMP-1) et MMP-13 induites par (Interleukine-1β) l’IL-1β. Cette diminution de la production protéique est accompagnée d’une diminution de l’expression au niveau de l’ARNm, et d’une diminution de l’activité du promoteur de MMP-1 et MMP-13. Cet effet est exercé via le récepteur D prostanoïde (DP1), bien que le Chemoattractant receptor expressed on Th2 cells (CRTH2) soit également exprimé chez les chondrocytes humains, mais ne semble pas être impliqué dans l’effet observé. Cette action inhibitrice se fait via la voie DP1/AMPc/protéine kinase A (AMPc/PKA).
Dans la suite de nos travaux, nous avons montré pour la première fois l’expression des prostaglandines D-synthases responsables de la biosynthèse de la PGD2 au niveau des chondrocytes humains par immunohistochimie, avec des niveaux d’expression de l’ARNm plus élevés de la L-PGDS au niveau du cartilage OA comparativement au cartilage normal. L’IL-1β pourrait être responsable de cette augmentation via l’activation de la voie JNK et p38 MAPK, ainsi que par la voie NF-κB.
L’ensemble de ces données indiquent que la modulation des niveaux de la PGD2 au niveau de l’articulation pourrait être pourvue d’un important potentiel thérapeutique. La L-PGDS pour sa part semble avoir un rôle important dans la physiopathologie de l’OA. / Osteoarthritis (OA) is the most common joint disease world wide, because of its higher socioeconomic impact it is one of the most studied joint diseases. The aims of these studies was to determine the molecular mechanisms involved in the pathophysiology of osteaarthritis. Previous studies have mainly focused on the involvement of prostaglandin (E2) PGE2 in contrast to PGD2 in the pathogenesis osteoarthritis as such the role of PGD2 remains unclear. In this thesis we examined the involvment of PGD2 in the pathogenesis of OA.
In the first part of our work, we showed that in a dose dependent manner PGD2 decreased the interleukin-1β (IL-1β)–induced mettalloproteases (MMP-1) and MMP-13 expression both at protein and mRNA levels by supression of their promoter activity. The inhibitory effect was exerted via the D prostanoid receptor (DP1) and mediated through the cAMP/protein kinase A (PKA) signalling pathway. Although human chondrocytes do express the Chemoattractant Receptor Expressed on Th2 cells (CRTH2) the latter were not implicated in the inhibiton of MMP-1 and MMP-13.
In the second part of our work, we showed the expression of prostaglandin D synthases (PGDS) responsible for the biosynthesis of PGD2 in human chondrocytes, with higher levels of mRNA expression of lipocaline type prostaglandin D-synthase (L-PGDS) in OA cartilage compared to normal cartilage. IL-1β may be responsible for this increase via the activation of Jun N-terminal kinase (JNK) and p38 mitogen activated protein kinase (MAPK), as well as the nuclear factor-κB (NF-κB).
Together, these data indicate that modulation of the levels of PGD2 at the joint may be provided with an important therapeutic potential. L-PGDS in turn seems to have an important role in the pathogenesis of OA.
|
10 |
PGD2 e inflamação eosinofílica: mecanismos moleculares e potencial como alvo terapêuticoSantos, Fabio Pereira Mesquita dos January 2011 (has links)
Submitted by Anderson Silva (avargas@icict.fiocruz.br) on 2012-11-30T11:59:08Z
No. of bitstreams: 1
fabio_p_m_santos_ioc_bcm_0037_2011.pdf: 10305796 bytes, checksum: 74de5b830c8354cd532f74bd40993c6a (MD5) / Made available in DSpace on 2012-11-30T11:59:08Z (GMT). No. of bitstreams: 1
fabio_p_m_santos_ioc_bcm_0037_2011.pdf: 10305796 bytes, checksum: 74de5b830c8354cd532f74bd40993c6a (MD5)
Previous issue date: 2011 / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil. / Durante a resposta alérgica, dentre os vários mediadores inflamatórios de natureza
lipídica, a prostaglandina D2 (PGD2) é considerada um mediador-chave. Em adição aos seus
conhecidos efeitos quimiotáticos para eosinófilos, recentemente, foi descrito que a PGD2 é
também capaz de promover a ativação dos eosinófilos, induzindo a biogênese de corpúsculos
lipídicos e a síntese de leucotrieno C4 (LTC4) nessas organelas recém-formadas. Esses efeitos
são atribuídos a ação da PGD2 sobre seus 2 receptores – DP1 e DP2 – os quais encontram-se
expressos de maneira constitutiva na membrana dos eosinófilos. Então, o objetivo principal do
estudo foi identificar o receptor específico da PGD2 envolvido no mecanismo de síntese de
LTC4 por eosinófilos estimulados com PGD2.
In vivo, num modelo murino de pleurisia alérgica e induzida por PGD2, a utilização
dos antagonistas seletivos do receptor DP1 (BW A868c) ou do receptor DP2 (CAY10471)
inibiu a síntese de LTC4 nessas respostas inflamatórias. No entanto, somente BWA868C foi
capaz de inibir a biogênese de corpúsculos lipídicos nos eosinófilos recrutados para o sítio
inflamatório; enquanto que o tratamento com o CAY10471, diminuiu o número de eosinófilos
infiltrantes na cavidade pleural, mas não inibiu a biogênese de corpúsculos lipídicos nessas
poucas células recrutadas. In vitro, eosinófilos humanos purificados estimulados com PGD2
tiveram a síntese de LTC4 inibida tanto pelo pré-tratamento com BWA868c, quanto pelo prétratamento
com CAY10471. Além disso, a ativação do receptor DP1, com seu agonista
seletivo (BW245c) e a ativação do receptor DP2 com o agonista seletivo do receptor DP2
(DK-PGD2) corroborou a observação de que no processo de síntese de LTC4 nos eosinófilos,
ambos os receptores são necessáior, pois somente quando ambos os receptores foram ativados
simultaneamente foi observada síntese de LTC4 nos corpúsculos lipídicos recém-formados
(Eicosacell). Além disso, caracterizamos que uma das vias de sinalização intracelular
envolvida na formação de corpúsculos lipídicos é depende da ativação de proteína quinase A
(PKA).
Em um outro grupo de ensaios, investigamos a PGD2 como potencial alvo terapêutico
em doenças alérgicas. Recentemente, foi descrito que o extrato aquoso de C. sympodialis e a
warafteína (alcalóide isolado) têm propriedades antialérgicas, visto que não somente reduzem
a eosinofilia, mas também, a biogênese de corpúsculos lipídicos, assim como a produção de
leucotrienos cisteinados. Dessa forma, aqui demonstramos que os pré-tratamentos tanto com o
extrato quanto com o alcalóide isolado, foram capazes de inibir a produção de PGD2 ocorrida
durante a resposta alérgica. In vitro, embora a warafteína não tenha inibido a biogênese de
corpúsculos lipídicos em eosinófilos induzida por PGD2, observamos que é capaz de bloquear
a liberação de PGD2 por mastócitos ativados – mas, não a produção de PGE2 por macrófagos
ativados com A23187 – demonstrando que o mecanismo de ação dos seus efeitos
antiinflamatórios não parecem envolver antagonismo de receptores em eosinófilos, e sim
inibição da síntese da PGD2 em sítios alérgicos. / During allergic response, among several lipid mediators produced, prostaglandin D2
(PGD2) has emerged as key mediator. In addition to its known eosinophilotatics effects,
recently PGD2 was described to be able to promote eosinophil activation, inducing lipid
bodies biogenesis and LTC4 synthesis within these newly formed organelles. These effects are
attributed to the action of PGD2 on its 2 receptors – DP1 e DP2 – which are expressed
constituvely on eosinophil cell membranes. So, the main objective of this study was to
identify the PGD2 specific receptor involved in LTC4 synthesis mechanism by stimulated
eosinophils with PGD2.
In vivo, in a murine allergic model of pleurisy and in a pleurisy induced by PGD2, the
use of selective DP1 receptor (BWA868c) and DP2 receptor (CAY10471) antagonists showed
us that both treatments inhibited LTC4 synthesis during these inflammatory responses.
However, only BWA868C treatment was able to inhibit lipid bodies biogenesis within
recruited eosinophils to the inflammatory sites, while CAY10471, decreased the number of
infiltrated eosinophils in the pleural cavity, but did not inhibit lipid bodies biogenesis within
these low number of recruited cells. In vitro, pre-treatment with BWA868c or CAY10471
inhibited LTC4 synthesis by human eosinophils stimulated with PGD2. Moreover, the
activation of DP1 receptor with its selective agonist (BW245c) and DP2 activation with DP2
selective agonist (DK-PGD2) reinforced the observation that during LTC4 synthesis within
eosinophils, activation of both receptors are necessary, because only simultaneous activation
of DP1 and DP2, induced LTC4 synthesis within eosinophilic lipid bodies (Eicosacell).
Moreover, we observed that the pathway of cellular signaling involved on lipid bodies
biogenesis induced by DP1 activation is dependent on protein kinase A (PKA).
In another set of experiments, we investigated PGD2 as a therapeutical target of
allergic diseases. Recently, it was described that aqueous extract of C.sympodialis and
warafteine (isolated alkaloid) have antiallergic properties, because of its effects on the
reduction of eosinophils recruitment, lipid bodies biogenesis and cysteinyl leukotrienes
synthesis. Here, we demonstrated that pre-treatments with extract and its alkaloid were able
to inhibit PGD2 production during allergic response. In vitro, warafteine did not inhibit
eosinophil lipid bodies biogenesis induced by PGD2, but it was capable to inhibit PGD2
release by activated mast cells – otherwise fail to blockade PGE2 production by A23187-
activated macrophages – suggesting that the action mechanism of its antiinflammatory effects
could occur through PGD2 synthesis inhibition in allergic sites.
|
Page generated in 0.0183 seconds